Fujitsu Limited
Fujitsu Japan builds a “cancer genome medical integrated system” for Shizuoka Cancer Center that supports genome testing that combines whole genome analysis and RNA sequencing
Contributing to the development of cancer genomic medicine and healthcare DX ……
Fujitsu Japan Ltd. (hereinafter referred to as “Fujitsu Japan”), in collaboration with Shizuoka Prefectural Shizuoka Cancer Center (Location: Sunto District, Shizuoka Prefecture, President: Katsuhiko Uesaka, hereinafter referred to as Shizuoka Cancer Center), has recently announced that it will be conducting whole genome analysis and We have developed a “cancer genome medical integrated system (cancer genome testing operations support/report creation system)” that is compatible with genome testing that uses RNA sequencing (Note 1).
This system enables the creation of reports with the amount and quality of information required for whole genome analysis in clinical settings, reducing the workload of medical professionals. In addition, we have newly realized integrated analysis of whole genome analysis results and RNA sequencing results, and by accumulating a huge amount of information such as these analysis results as data and utilizing it for future drug development and treatment, We will support the return of more accurate information to patients and contribute to the social implementation of genomic medicine.
[Current status of cancer genomic medicine]
Cancer genomic medicine is a type of personalized medicine that considers cancer treatment plans based on the patient’s individual genetic mutations. In Japan, cancer genome profiling tests were covered by insurance in 2019, and cancer genome medicine in clinical settings has gained momentum. Demonstrative research on whole genome analysis for cancer is currently underway in order to utilize the analysis results in clinical settings, based on the “Whole Genome Analysis Implementation Plan” promoted by the Ministry of Health, Labor and Welfare.
While these genomic tests can suggest more appropriate treatments for each patient, medical professionals are burdened with the task of compiling a variety of patient information, including the results of genomic tests. Particularly in whole genome analysis, the amount of information obtained is enormous, and advanced and specialized skills are required to extract important information for determining patient treatment plans. Therefore, the number of people who can engage in this work is limited, and this is one of the challenges for the spread of cancer genomic medicine and the development of whole genome analysis.
[About the “Cancer Genome Medical Integrated System”]
Fujitsu Japan and Shizuoka Cancer Center have developed a new “Cancer Genome Medical Integrated System (Cancer Genome Testing Support/Report Creation System)” with the aim of expanding patient returns such as whole genome analysis results. did.
[Image: https://prtimes.jp/i/93942/276/resize/d93942-276-34c3b08612cf8180dc58-0.png&s3=93942-276-22788bb1d97dfc2a4014c03e5e994877-950×528.png ]
Figure 1. System overview diagram
[Main features]
1. Semi-automation of test result report creation and data
accumulation with a view to utilizing genomic data
This system is an improved version of the genome testing support system (Note 2) provided by Fujitsu Japan, and is capable of centrally managing large volumes of genomic data such as whole genome analysis results and RNA sequencing results. With this system, the results of genome testing including whole genome analysis and clinical
information can be imported into the system, and in addition to automatically adding information from public databases and research information to detected genetic changes, Shizuoka Cancer It is possible to semi-automatically create a draft of a verification result report based on the center’s knowledge, reducing the burden on medical professionals in creating reports. In addition, by accumulating all information, including the interpretations and considerations of medical professionals added to the report, in a database, it can be used not only for the evaluation of subsequent cases, but also for new treatment development research and pathological analysis. Data can be used in research.
2. Improving the accuracy of genetic change information provided to patients through integrated analysis of whole genome analysis and RNA sequencing (Note 3)
This system uses integrated analysis of whole genome analysis and RNA sequencing to improve the accuracy of information on genetic changes provided to patients, provide information that can be used as a reference for determining treatment plans for patients, and improve the evaluation of test results. This will reduce the burden. 【About the future】
Based on this case study, Fujitsu Japan will strengthen the
functionality of its services and develop technology to automatically create reports using generative AI, and will deploy this to facilities involved in cancer genomic medicine. We will also contribute to the realization of healthcare DX by utilizing digital technology and technology for the social implementation of next-generation cancer genomic medicine.
[About trademark]
Proper nouns such as product names listed are trademarks or registered trademarks of each company.
[Note]
Note 1
RNA sequencing A technology that comprehensively reads and analyzes RNA sequence information using a next-generation sequencer.
Note 2
Genome testing support system Fujitsu Genome solution “HOPE
LifeMark-GiMS” genome testing support system”
(https://www.fujitsu.com/jp/solutions/industry/healthcare/products/lifemarkgims/) Note 3
Integrated analysis of whole genome analysis and RNA sequencing Based on the genome analysis technology of cBioinformatics Inc. (location: Chiyoda-ku, Tokyo, CEO: Shigeo ), which collaborates with Fujitsu Japan, and the know-how of Shizuoka Cancer Center. This is achieved by performing analysis.
【Related Links】
・Shizuoka Cancer Center Press Release
(https://www.scchr.jp/press/press_20240325.html)
・Fujitsu Genome Solution “HOPE LIfeMark GiMS”
(https://www.fujitsu.com/jp/solutions/industry/healthcare/products/lifemarkgims/) ・cBioinformatics Co., Ltd.
(https://www.cbioinformatics.com/)
[Inquiries regarding this matter]
HOPE LifeMark-GiMS contact fjj-contact-gims@cs.jp.fujitsu.com Product prices, specifications, service content, etc. stated in the press release are as of the date of announcement. It is subject to change without prior notice. Please note.
More details about this release:
https://prtimes.jp/main/html/rd/p/000000276.000093942.html